NASDAQ:ARTL Artelo Biosciences Q3 2026 Earnings Date & Estimates $2.55 0.00 (0.00%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$2.49 -0.06 (-2.31%) As of 10/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Artelo Biosciences is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 17, 2026TimeBefore Market OpensConference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Artelo Biosciences in Q3 2026Artelo Biosciences is expected to post earnings of -$7.02 per share. In the same quarter a year earlier Artelo Biosciences reported -$107.19 per share. Artelo Biosciences last reported on August 12, 2026, posting -$0.89 per share and beating the -$6.48 consensus estimate.Consensus EstimatesConsensus EPS-$7.02Prior-Year EPS-$107.19Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.89 (Beat by +$5.59)Prepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Artelo Biosciences Q3 2026 Earnings FAQ When does Artelo Biosciences report Q3 2026 earnings? Artelo Biosciences (NASDAQ:ARTL) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Artelo Biosciences' Q3 2026 earnings call? Artelo Biosciences' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Artelo Biosciences? Analysts expect Artelo Biosciences to post earnings of -$7.02 per share for Q3 2026. Artelo Biosciences Earnings HeadlinesArtelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-EuropeOctober 7, 2026 | rttnews.comArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformOctober 7, 2026 | globenewswire.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)Artelo Biosciences (ARTL)September 23, 2026 | es.investing.comArtelo Expands ART27.13 Patent Coverage After Obesity Study FindingsSeptember 23, 2026 | rttnews.comArtelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?September 23, 2026 | benzinga.comSee More Artelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email. Email Address About Artelo BiosciencesArtelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system. The company is pursuing treatments for cancer, pain, inflammation and other conditions in which cannabinoid receptors and related biological pathways may play a role. Artelo’s development pipeline has included ART12.11, a proprietary cannabidiol-based pharmaceutical composition being investigated for potential use in oncology, and ART26.12, a fatty acid amide hydrolase inhibitor designed for potential applications in cancer-related pain and inflammatory disorders. The company has also evaluated ART27.13, a peripherally restricted cannabinoid receptor agonist intended to address appetite loss and cancer-related anorexia. Artelo Biosciences was established to advance cannabinoid-based medicines through pharmaceutical development rather than relying on traditional botanical cannabis products. The company is based in San Diego, California, and its programs have been developed for potential use in international markets, subject to clinical and regulatory approval. Gregory D. Gorgas has served as the company’s president and chief executive officer.View Artelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
